scPharmaceuticals (SCPH) to Release Earnings on Thursday

Key Points

• scPharmaceuticals is set to announce its Q2 2025 earnings on August 7th, with analysts forecasting a loss of ($0.30) per share and revenue of $15.41 million.
• The company reported a loss of ($0.34) EPS in its last earnings release, missing estimates, along with a negative return on equity of 594.07%.
• Institutional investors currently own 89.52% of scPharmaceuticals stock, with recent increases in stakes from notable firms like Comerica Bank and Rhumbline Advisers.

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) will likely be posting its Q2 2025 quarterly earnings results before the market opens on Thursday, August 7th. Analysts expect scPharmaceuticals to post earnings of ($0.30) per share and revenue of $15.41 million for the quarter.

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.06). scPharmaceuticals had a negative return on equity of 594.07% and a negative net margin of 216.24%. The firm had revenue of $11.75 million during the quarter, compared to the consensus estimate of $11.63 million. On average, analysts expect scPharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

scPharmaceuticals Price Performance

Shares of scPharmaceuticals stock traded down $0.02 during trading on Monday, hitting $5.15. 19,146 shares of the company's stock traded hands, compared to its average volume of 378,803. The company has a market cap of $272.03 million, a PE ratio of -2.73 and a beta of 0.40. scPharmaceuticals has a twelve month low of $1.94 and a twelve month high of $6.28. The company has a debt-to-equity ratio of 3.86, a current ratio of 5.48 and a quick ratio of 4.61. The firm's fifty day moving average price is $4.30 and its 200 day moving average price is $3.41.

Hedge Funds Weigh In On scPharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC bought a new stake in shares of scPharmaceuticals during the first quarter worth approximately $76,000. Comerica Bank increased its stake in scPharmaceuticals by 22.1% in the first quarter. Comerica Bank now owns 38,662 shares of the company's stock valued at $102,000 after purchasing an additional 7,000 shares in the last quarter. Finally, Rhumbline Advisers boosted its holdings in shares of scPharmaceuticals by 21.0% in the first quarter. Rhumbline Advisers now owns 51,499 shares of the company's stock valued at $135,000 after buying an additional 8,945 shares during the period. 89.52% of the stock is currently owned by institutional investors and hedge funds.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.